Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13515713 | 1.00 | MAPT (0.57) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL3034810 | 0.90 | MAPT (0.56) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL13515719 | 0.90 | MAPT (0.56) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL13515707 | 0.87 | MEN1 (0.58) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL3045796 | 0.87 | MEN1 (0.58) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL13515655 | 0.86 | ABCB1 (0.57) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL3255019 | 0.86 | ABCB1 (0.57) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL3042761 | 0.86 | MEN1 (0.56) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL3042690 | 0.86 | MEN1 (0.56) | MAPTMEN1KMT2ALMNAALOX15 | |
| SCHEMBL4479912 | 0.86 | MEN1 (0.56) | MAPTMEN1KMT2ALMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-7642262-B2 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2010-01-05 | — | — | US | disclosed |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-0958280-B1 | ARYLPIPERIDINOPROPANOL AND ARYLPIPERAZINOPROPANOL DERIVATIVES AND PHARMACEUTICALS CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
| US-6838470-B2 | Arylpiperidinopropanol and arylpiprazinopropanol derivatives and pharmaceuticals containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-04 | — | — | US | disclosed |
| EP-1138678-B1 | Process for making N-((4-phenyl) methylphenyl) piperazines | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | ASUBIO PHARMA CO., LTD. (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6525199-B1 | Ring coupling, reduction and deprotecting; synthesis of compounds for alleviation and treatment of symptoms due to ischemic diseases | SUNTORY LIMITED (JP) | 2003-02-25 | — | — | US | disclosed |
| US-6407099-B1 | SUPPRESSING CYTOTOXIC CALCIUM OVERLOAD AND LIPID PEROXIDATION; ANTIEPILEPTIC, ANTIISCHEMIC, AND ANTIEDEMIC AGENTS; BRAIN, NERVOUS SYSTEM, AND CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1138678-A2 | Process for making N-((4-phenyl) methylphenyl) piperazines | SUNTORY LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236269-A1 | Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, APOL1 | MAPT 3808/4885MEN1 4841/4885KMT2A 4002/4885 |
| US-20050101610-A1 | Arylipiperdinopropanol and arylipiperazinopropanol derivatives and pharmaceuticals containing the same | NR1H2, NR1H3, NR3C2 | MAPT 4246/4885MEN1 4756/4885KMT2A 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.